Drug Profile


Alternative Names: IXA 001; SL 810385

Latest Information Update: 10 Jun 2016

Price : $50

At a glance

  • Originator Sanofi-Synthelabo
  • Developer IXALTIS
  • Class Antidepressants; Piperidines; Small molecules
  • Mechanism of Action Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Urinary incontinence
  • Discontinued Major depressive disorder

Most Recent Events

  • 10 Jun 2016 Discontinued - Phase-III for Major depressive disorder in France (PO)
  • 30 May 2016 Preclinical trials in Urinary incontinence in France (PO)
  • 30 May 2016 IXALTIS plans a phase II trial for Urinary incontinence in France
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top